Mendel
Automates matching cancer patients to clinical trials through personal medical history and genetic analysis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | $40.0m | Series B | |
| Total Funding | 000k | ||
Related Content
Mendel.ai is a pioneering startup based in the United States, founded in 2016, that leverages artificial intelligence (AI) to transform the landscape of clinical data analysis. The company primarily operates in the healthcare sector, focusing on oncology research and clinical trials. Mendel.ai's innovative AI tools analyze vast amounts of clinical data, including electronic medical records (EMR) and genetic information, to facilitate the identification of suitable cancer patients for clinical trials. This process significantly accelerates the matching of patients to the right trials, which can otherwise be a time-consuming and complex task.
Mendel.ai serves a diverse range of clients, including researchers, epidemiologists, clinicians, and pharmaceutical companies. By providing a robust AI-powered platform, Mendel.ai helps these clients make sense of large datasets, enabling them to draw meaningful insights quickly and efficiently. For instance, the company has developed an AI search engine that can analyze over 50,000 scholarly articles related to COVID-19, allowing users to find relevant information in seconds.
The market Mendel.ai operates in is the rapidly growing field of healthcare AI, particularly focusing on real-world evidence (RWE) and real-world data (RWD) in clinical settings. This market is driven by the increasing need for efficient data analysis tools that can handle the complexity and volume of modern medical data.
Mendel.ai's business model revolves around providing subscription-based access to its AI platforms and tools. Clients pay for the ability to use Mendel.ai's technology to analyze their clinical data, streamline their research processes, and improve patient outcomes. The company also offers customized solutions and consulting services to meet the specific needs of its clients.
In summary, Mendel.ai is revolutionizing clinical data analysis with its AI technology, serving the healthcare sector by improving the efficiency and accuracy of clinical trials and research.
Keywords: AI, clinical data, oncology, clinical trials, healthcare, EMR, genetic analysis, COVID-19, RWE, RWD.